Vendor Intelligence Report: PeptiSlim

Executive summary

PeptiSlim reads less like a domestic US peptide retailer and more like a cross-border factory-to-consumer channel. Its own COAs name Limeiren Trading Store as manufacturer and elitepeptide66.com as client. Contact records tie Bella/Xabelle Fu and Emily to Hong Kong numbers, with Emily bridged to a Limeiren supplier-facing TikTok account. The site markets 10+ years experience, but domain and Wayback records tell a much shorter public retail story, and no reviewed US page disclosed a legal entity or physical address.

Across 61 Finnrick lab tests, PeptiSlim shows 50 pass / 11 fail for an 82% overall pass rate. The buyer read is product-specific: Retatrutide is one of the stronger tested choices, Tirzepatide sits above the weak end but carries a documented identity-failure event, and Tesamorelin/Cagrilintide are poor blind buys. Public purity-focused scoring is also more forgiving than stricter fill-accuracy grading.

The non-lab record raises its own friction. The Australian deployment is a separate WordPress site with non-Australian placeholder-style addresses, a public statement that bank records will show an undisclosed generic Australian business name, and no PeptiSlim ABN found in the field run. A reported Lean Life Peptides advertising lineage, shared Wellness & Peptide Solutions contact details, and Philippines-facing reseller leads add channel-verification risk.

The practical conclusion is narrow: PeptiSlim may be defensible only for specific better-tested products with batch-level verification, not as a comfortable blind-reorder vendor. The full report connects the lab dispersion to COAs, platform traces, regulatory exposure, and open leads for re-checking the operation.

Inside the full report:

• Per-product pass/fail rates, trajectory views, and methodology-divergence charts for all six tested products
• COA analysis tying elitepeptide66.com to Limeiren Trading Store and open Janoshik task-number checks
• Operator map covering Bella/Xabelle Fu, Emily, Hong Kong contact channels, and the Limeiren TikTok bridge
• Australian-site evidence: placeholder addresses, hidden payment-descriptor language, and ABR search result
• Infrastructure and timeline records for Shoplazza, CNDNS/RDAP, Wayback captures, and brand-lineage leads
• Regulatory analysis for US Tirzepatide shipments, Australian peptide enforcement, and buyer recourse limits

Risk assessment

• Product-specific quality risk — high: Finnrick shows 61 tests (50 pass / 11 fail): GHK-Cu 87.05%, Retatrutide 86.89%, and Tirzepatide 83.33% are stronger, but Tesamorelin 44.4%, Cagrilintide 55.21%, Semaglutide 70.71%, and a Tirzepatide identity-failure certificate make blind buying high risk.
• Traceability and batch-control risk — high: Vendor COAs reviewed cluster on one Feb. 2026 Janoshik submission; sample records show inconsistent/no batch IDs and a shared SHJN-11172025 code across Retatrutide and Tesamorelin.
• Operator transparency risk — high: No legal entity or physical address is disclosed on the U.S. storefront; AU pages show placeholder addresses and a bank statement name deliberately withheld from public view.
• Regulatory and seizure risk — high: U.S. Tirzepatide orders face ITC 337-TA-1377 exclusion-order exposure; AU peptide sales face TGA enforcement and no PeptiSlim ABN was found in ABR search.
• Brand-confusion and channel-verification risk — medium: PeptiSlim spans elitepeptide66.com, peptislim.com/AU, a reported Lean Life Peptides lineage, Telegram/social mentions, and reseller channels without an official channels or authorized-reseller list.